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Abstract
Background: Reproductive disorders, such as polycystic ovary syndrome (PCOS), primary ovarian insufficiency (POI)
and hypertensive pregnancy disorders (HPD) like pre-eclampsia (PE), are associated with an increased risk of
cardiovascular disease (CVD). Detection of early signs of cardiovascular disease (CVD), as well as identification of
risk factors among women of reproductive age which improve cardiovascular risk prediction, is a challenge and
current models might underestimate long-term health risks. The aim of this study is to assess cardiovascular
disease in patients with a history of a reproductive disorder by low-dose computed tomography (CT).
Methods: Women of 45 - 55 years, who experienced a reproductive disorder (PCOS, POI, HPD), are invited to participate
in this multicenter, prospective, cohort study. Women will be recruited after regular cardiovascular screening, including
assessment of classical cardiovascular risk factors. CT of the coronary arteries (both coronary artery calcium scoring
(CACS), and contrast-enhanced coronary CT angiography (CCTA)) and carotid siphon calcium scoring (CSC) is planned
in 300 women with HPD and 300 women with PCOS or POI. In addition, arterial stiffness (non-invasive pulse
wave velocity (PWV)) measurement and cell-based biomarkers (inflammatory circulating cells) will be obtained.
Discussion: Initial inclusion is focused on women of 45 - 55 years. However, the age range (40 - 45 years and/or
≥ 55 years) and group composition may be adjusted based on the findings of the interim analysis. Participants
can potentially benefit from information obtained in this study concerning their current cardiovascular health and
expected future risk of cardiovascular events. The results of this study will provide insights in the development of
CVD in women with a history of reproductive disorders. Ultimately, this study may lead to improved cardiovascular
prediction models and will provide an opportunity for timely adjustment of preventive strategies. Limitations of this
study include the possibility of overdiagnosis and the average radiation dose of 3.5 mSv during coronary and carotid
siphon CT, although the increased lifetime malignancy risk is negligible.
Trial registration: Netherlands Trial Register, NTR5531. Date registered: October 21st, 2015.
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Background
Reproductive disorders, including polycystic ovary syn-
drome (PCOS), primary ovarian insufficiency (POI) and
hypertensive pregnancy disorders (HPD) such as pre-
eclampsia (PE), are associated with an increased risk of
cardiovascular diseases (CVD).
Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) has a prevalence of
around 8 to 10% in Caucasian women and is the most
common endocrine disorder in women of reproductive
age [1]. According to the Rotterdam consensus criteria,
PCOS is diagnosed when at least two of the following
criteria are present: (i) oligo−/anovulation, (ii) clinical
and/or biochemical hyperandrogenism, and (iii) polycys-
tic ovaries on ultrasonography [2]. Insulin resistance,
dyslipidemia and type 2 diabetes mellitus (T2DM) have
been associated with PCOS [3–7].
Increasingly PCOS has been associated with cardiovas-
cular risk factors, such as impaired glucose tolerance,
obesity, metabolic syndrome (MetS) and hypertension.
Several studies have ascertained premature signs of sub-
clinical arterial disease in women with PCOS, such as
abnormal carotid intima media thickness on ultrasound
or coronary artery calcification score (CACS) on com-
puted tomography (CT) [8–10]. Nevertheless, evidence
on the potential association between PCOS and CVD
endpoints is still limited [11–13].
Primary ovarian insufficiency
Primary ovarian insufficiency (POI), formerly known as
premature ovarian failure, is characterized by secondary
amenorrhea for at least 4 months accompanied by ele-
vated FSH levels above 40 IU/L, before 40 years of age
[14]. The incidence of POI is reported to be 1-2% [15, 16].
POI is associated with elevated gonadotropins, hypoestro-
genemia and hypoandrogenemia.
Early age at menopause, including POI, is associated
with an increased incidence of coronary heart disease
and CVD mortality [17–19]. Epidemiological data
showed that the relative risk (RR) on CVD was 1.03
(95% confidence interval (CI) 1.01 – 1.05) for each 1-
year decrease in age at menopause [19]. Hypoandrogen-
emia in women has been associated with an increased
risk of atherosclerosis, as measured by CIMT or catheter
angiography [20–23] and CVD events [24]. A recent sys-
tematic review and meta-analyses identified POI as an
independent, modest risk factor for developing or dying
from IHD (ischemic heart disease) (hazard ratio (HR)
1.69, 95% CI 1.29-2.21, p = 0.0001) and total CVD (HR
1.61, 95% CI 1.22-2.12, p = 0.0007) [25]. No relationship
was found for POI and stroke (HR 1.03, 0.88 - 1.19, p =
0.74). These findings may implicate a decreased cardio-
vascular health in women with POI. However, like
PCOS, it remains unclear to which extent POI is inde-
pendently associated with CVD due to the paucity of
data.
Hypertensive pregnancy disorders
HPD include pregnancy-induced hypertension (PIH),
PE and the hemolysis, elevated liver enzymes, low
platelets (HELLP) syndrome. Together, this group of
disorders complicates 5-12% of all pregnancies world-
wide, [26] while PE alone is seen in 3-5% of all preg-
nancies [27, 28]. Several studies showed that both
classical CVD risk factors and novel serum biomarkers
for CVD were increased in former hypertensive preg-
nancies (PIH, late-onset PE and especially early-onset
PE) compared to normotensive pregnancies in both
premenopausal and postmenopausal women [29, 30].
Major CVD risk factors (e.g. hypercholesterolemia, hyper-
tension, diabetes and MetS) were 3-4 fold more prevalent
in formerly pre-eclamptic patients when compared with
healthy controls of the same age at one to three years after
index pregnancy [31–33]. However, mainly due to the
relative young age (mean 30.5 years), the 10-year absolute
risk of a CVD event as estimated by the Framingham Risk
Score (FRS) was still low (mean estimated 10-year cardio-
vascular disease risk 1.08%) [31].
Women who were diagnosed with pre-eclampsia have
a twofold future CVD risk [34–38]. The relative risk of
developing hypertension later in life in women with a
history of pre-eclampsia is 3.74 [39]. Moreover, the risk
of developing diabetes later in life is also 2-3 times in-
creased in women with a history of pre-eclampsia com-
pared to women without such a history [40–42]. These
findings have led to the hypothesis that pregnancy acts
as a stress-test for CVD later in life [43].
The sub-analyses of a longitudinal follow-up study of
the HYPITAT trial – the HyRAS study – showed neither
significant differences in hypertension and biochemical
cardiovascular risk factors postpartum, nor a difference
in the estimated 10- and 30 year Framingham cardiovas-
cular event risk, between women with a history of late-
onset pre-eclampsia compared to women with PIH [32].
On the other hand, the increased CVD risk does appear
to be more pronounced in the subgroup of early-onset
of pre-eclampsia (generally defined as pre-eclampsia oc-
curring before 34 weeks of gestation), with a RR of 7 to
8 on IHD and death due to IHD [34, 35].
Despite recent advances in long-term follow-up after
reproductive disorders, identifying women at increased
risk for premature CVD remains a challenge. The use of
the FRS and other risk models for IHD, like the Systematic
Coronary Risk Evaluation (SCORE), Reynolds risk score
and the Pooled Cohort Equations, are limited by their
underestimation of lifetime CVD risk in young women.
The recently published Dutch guideline “Cardiovascular
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Risk Management after Reproductive Disorders” recom-
mends all women with a history of a reproductive disorder
to optimize lifestyle factors [44]. Patients with a history of
pre-eclampsia are advised to generate a risk profile at
50 years of age, as their risk of hypertension and diabetes
mellitus is increased and the onset of these cardiovascular
risk factors is up to 7 years earlier compared to women
without pregnancy complications [39, 45]. However, longi-
tudinal follow-up data on biomarkers, signs and symp-
toms of premature subclinical atherosclerosis are needed
to better identify the potential adverse effects of female-
specific risk factors and life-events on CVD risk.
Serum biomarkers
Circulating endothelial cells, extracellular vesicles and
circulatory inflammatory cells might lead to discovery of
new biomarkers for women with reproductive disorders
which are at risk for CVD development.
Both HPD and CVD later in life share a pathophysio-
logic pathway of vascular (endothelium) damage. Pre-
eclampsia is associated with an increased number of
circulating endothelial cells due to a high degree of
endothelial cell activation or injury. Extracellular vesicles
(e.g. microvesicles, exosomes) reflect the disease state of
pre-eclampsia patients compared to healthy pregnant
women [46, 47]. In addition, extracellular vesicles -asso-
ciated polygenic immunoglobin receptor, cystatin C, and
complement factor C5a are markedly increased in pa-
tients suspected of acute coronary syndrome [48]. As
EVs might be involved in both reproductive disorders
and CVD, they could possibly serve as a biomarker.
The inflammatory profile of circulating cells is proven
to be very different in women suffering from CVD [47].
For example, carotid plaques show sex-dependent in-
flammatory cell content, including neutrophils [49].
Imaging
CACS acquired with CCT has been shown to have su-
perior predictive value for CVD events to traditional risk
factors, risk factor scores and serum biomarkers in
asymptomatic persons [50]. Contrast-enhanced CCTA
may have additional value over CACS as it can also
identify non-calcified plaques, and thereby the total ath-
erosclerotic burden, and assess the presence of coronary
luminal narrowing [51–54]. As calcification of plaque
occurs at a relatively late stage in atherosclerosis, signifi-
cant coronary atherosclerosis may be visualized earlier
by visualizing the non-calcified coronary plaque with
CCTA. Data of CCT as a diagnostic tool, i.e. CACS or
CCTA, is scarce and inconclusive for women with repro-
ductive disorders.
Several studies have assessed the presence of coronary
calcium in PCOS. Although some of these studies
showed an increased CACS in women with PCOS, a
recent large, cross-sectional study could not find an as-
sociation with PCOS and CACS [55–58].
In a retrospective cohort study published in 2007, the
relation between HPD and coronary calcification later in
life was assessed in 491 women (mean age 66.8 years,
standard deviation 5.4 years) [59]. Coronary calcifica-
tions (Agatston score ≥ 1) were found in 305 women
(62.9%).This study showed that a self-reported history of
hypertension during pregnancy is related to higher
CACS in the 7th decade of life (Odds ratio (OR) 1.57,
95% CI 1.04 - 2.37). In an adjusted model correcting for
age, BMI, waist:hip ratio, systolic blood pressure and
diastolic blood pressure the relation did not reach statis-
tical significance anymore (OR 1.52, 95% CI 0.96 - 2.39)
[59]. Other retrospective studies assessing coronary ar-
tery disease (CAD) by catheter coronary angiography in
women suspected for CAD and with a history of HPD
showed contrasting results [60, 61]. A recent prospective
cohort study conducted among 40 former pre-eclamptic
women and 40 age- and parity-matched healthy controls
showed increased CACS in former pre-eclamptic women
at a mean age of 59.5 ± 4.6 years. The unadjusted OR
for having higher CACS due to preeclampsia was 3.54
(95% CI 1.39 - 9.02), although the adjusted model cor-
recting for BMI and hypertension did not reach statis-
tical significance anymore [62].
There is mounting evidence that intracranial carotid
artery calcifications are associated with increased large
artery and intracranial artery stiffness, as well as ische-
mic stroke, white matter abnormalities and cognitive
impairment [63, 64]. Recent studies found a relationship
between carotid siphon calcium (CSC) and white matter
hyperintensities and lacunar infarcts [65–67]. Other stu-
dies, however, could not confirm these findings [68–70].
Collectively, previous studies indicate an association
between women with reproductive disorders and CVD
later in life. Current risk profiles are inadequate to estab-
lish future CVD risk in still relative young premeno-
pausal women. The aim of this study is to assess the
diagnostic value of cell-based biomarkers, CCT imaging
(both non-contrast CACS and contrast enhanced
CCTA) and non-contrast CSC in patients with a repro-
ductive disorder to detect CVD.
Methods
Study design and study setting
In this multicenter, prospective, cross-sectional study of
patients with a reproductive disorder (PCOS, POI or
HPD) we aim to assess the diagnostic value of cell-
based biomarkers and CT imaging of the coronary ar-
teries and carotid siphon in the detection of CVD. Pa-
tients will be invited to participate at their regular
cardiovascular screening, which is performed at two large
Zoet et al. BMC Women's Health  (2017) 17:60 Page 3 of 9
University Medical Centers in Utrecht (UMC Utrecht)
and Rotterdam (Erasmus MC) in the Netherlands.
Participant characteristics
All patients with a reproductive disorder undergo regu-
lar cardiovascular screening at a specialized vascular out-
patient clinic in one of the participating hospitals as part
of standard care for cardiovascular diseases. The study
population consists of women aged 45-55 years within
three different groups:
1. Women with PCOS defined by Rotterdam consensus
criteria, requiring the presence of at least two of the
following criteria: (i) oligo−/anovulation, (ii) clinical
and/or biochemical hyperandrogenism, and (iii)
polycystic ovaries on ultrasonography.
2. Women with POI defined as women with secondary
amenorrhea for at least 4 months accompanied by
elevated FSH levels above 40 IU/L, occurring prior
to 40 years of age.
3. Women with a history of HPD (PIH, early-onset PE
(i.e. delivery before 34 weeks of gestation) and late-
onset PE (i.e. delivery after 34 weeks of gestation))
according to the ISSHP criteria, verified in clinical
records.
Patients with any serious illness that can compromise
study participation, patients with high risk for contrast
nephropathy (renal dysfunction with an estimated glom-
erular filtration rate < 60 ml/min/1.73 m2) or patients
with a history of myocardial infarction are excluded from
the study.
After written informed consent is obtained, patients
will undergo cardiovascular imaging assessment by
CCT imaging, biomarkers and a non-invasive vascular
measurement.
Coronary CT imaging
CCT is performed using a multislice CT scanner (256 slice
Philips CT, Philips Healthcare, Best, the Netherlands or
dual source Somaton Force or Drive Siemens CT,
Siemens, Forchheim, Germany) with prospective ECG-
triggering. A non-contrast coronary CT is acquired first
to calculate the CACS (scan parameters 120 kV, 50
mAs or reference mAs of 80 mAs). Participants with a
heart rate > 65 beats/min may receive an oral (25-50 mg)
and/or intravenous (5-20 mg) beta-blocker (metoprolol,
Selokeen AstraZeneca, Zoetermeer, the Netherlands) be-
fore the scan. All participants will receive sublingual nitro-
glycerine just before the CCTA. CCTA scan parameters
will be as follows depending on the participant’s weight:
1. For the Philips scanner a prospective ECG-triggered
acquisition is performed at a mid-diastolic phase
(78%) with 80-120 kV; 195-210 mAs; and 90–115 ml
non-ionic contrast material (Iopromide, 300 mg I/ml;
Ultravist, Bayer Healthcare, Berlin, Germany)
followed by 30–40 ml saline, both injected at a
speed of 6–6.7 ml/s. A bolus-tracking technique is
used to time the arrival of contrast in the coronary
arteries. The CCTA scan is initiated once a threshold
of 130 HU is reached in the descending aorta
followed by a 7-s post-threshold delay. CCTA’s
are reconstructed with 0.9 mm slice thickness and
iDose iterative reconstruction level 4 and 6.
2. For the Siemens scanners a sequential prospective
ECG–triggered acquisition is performed with a
pulsing window width depending on heart rate or a
high-pitch acquisition timed to image the heart in
diastole in case of low regular heart rate. KV and
mAs are selected using automatic KV selection
based on the topogram (range 70-120 kV) and a
reference mAs setting of 230 mAs at 120 kV. At
lower kVs reference mAs is automatically adapted
accordingly. Either a bolus-tracking technique or test
bolus injection with 10 ml contrast is used to time
the arrival of contrast in the coronary arteries at the
discretion of the technician. Non-ionic contrast
material (Iopromide, 370 mg I/ml; Ultravist, Bayer
Healthcare, Berlin, Germany) is used followed by 30-
40 ml saline, both injected at a speed of 5.4 ml/s.
Total contrast volume is calculated as scan time + 8 s
multiplied by contrast flow rate. Mostly around
70 ml of contrast is injected for the CCTA. CCTA’s
are reconstructed with 0.6 mm slice thickness and
ADMIRE iterative reconstruction level 3.
The total CCT radiation dose to which participants
will be exposed is expected to be within 3.0 mSv.
CT scans are post processed on a workstation (Intelli-
Space Portal, Philips Healthcare, QAngio CT software,
Medis Medical Imaging or SyngoVia,Siemens) by experi-
enced personnel. CACS is measured on the non-
contrast CT with the Agatston scoring method [71].
Coronary artery calcium is defined as a density of >130
Hounsfield units (HU) in a coronary artery. Total CACS
is calculated by the sum of all lesions in all four coronary
arteries and their side branches. The total Agatston
score will be categorized as no calcification (CACS = 0),
mild (CACS > 0 and < 100), moderate (CACS ≥ 100 and
< 400) and severe (CACS ≥ 400) calcification; and com-
pared with the MESA database [72]. Semi-automated
vessel analysis is used to make multiple curved multipla-
nar reconstructions (MPR) of all coronary arteries on
the CCTA data.
All cardiac CT scans will be assessed by an experi-
enced cardiovascular radiologist in both academic hospi-
tals. Image quality, plaque characteristics and coronary
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lumen stenosis will be analyzed on a 18-segment basis
according to the modified American Heart Association
classification [73, 74]. Plaque composition will be evalu-
ated in a qualitative manner as calcified, mixed (both
calcified and non-calcified components) and non-
calcified (plaques without calcium). Total atherosclerotic
plaque burden will be measured with both the segmental
involvement score (SIS) and the segment stenosis score
(SSS) based on the 18-segment coronary artery model
[74]. Luminal stenosis will be graded as absent, minimal
(1 – 24%), mild (25 – 49%), moderate (50 – 69%), and se-
vere (≥ 70%) narrowing on the basis of diameter mea-
surements comparing the diameters of the maximal
stenosis to a reference diameter proximal and distal to
the stenotic area [75]. If severe calcifications are present
and quantification of stenosis is difficult, the radiologist
will refrain from stenosis quantification and score the
segments involved as ‘calcified, stenosis unclear’.
Carotid siphon calcification imaging
A non-contrast CT with 20-40 mm coverage is planned
around the sella turcica to include the intracranial ca-
rotid siphon and anterior clinoid process. The head is
tilted with the chin towards the breast to avoid scanning
the eye lens. The CSC radiation dose to which partici-
pants will be exposed is expected to be less than
0.5 mSv on average. Scan parameters will be as follows:
1. For the Philips scanner: 20 mm coverage from petrous
apex to ICA top with 120 kV, 100 mAs, brain filter B
and C, iDose iterative reconstruction level 3, 1 mm
and 2 mm reconstruction thickness without overlap.
2. For the Siemens scanner (Somatom Force or Drive):
40 mm coverage from horizontal part of the petrous
ICA to ICA top with 120 kV, 100 mAs reference,
H31s and H45s head filter, 075 mm reconstruction
thickness and 0.4 mm increment.
The axial scans are visually assessed by a radiologist
for presence or absence of carotid siphon calcification.
The severity of CSC will be visually assessed and cate-
gorized according to Woodcock as 0 = absent, 1 =mild
(thin, discontinuous), 2 =moderate (thin, continuous or
thick, discontinuous) or 3 = severe (thick, continuous)
[76, 77]. In addition, the CSC will be semi-automatically
quantified as described in detail previously [65].
Single center side study: Serum biomarkers and non-
invasive vascular measurements
Classical cardiovascular biochemical risk factor assess-
ment (glucose, insulin, triglycerides, total cholesterol,
low-density lipoprotein cholesterol and c-reactive pro-
tein) and a general hematological profile (total red and
white blood cells and differential counts of nucleated
cells) will both be determined.
As part of a single center side study in the UMC
Utrecht, the neutrophil, monocyte, and lymphocyte cell
numbers and subtype distribution will be examined
based on established cell surface marker expression by
flow cytometry analysis [78, 79]. Peripheral blood
mononuclear cells and circulating endothelial cells will
be isolated and sorted directly after drawing blood. To
assess histone modification in inflammatory genes,
monocytes are cultured in the presence of atheroscler-
osis associated antigens (oxLDL, HSP). Plasma will be
used to isolate and detect (endothelial) microparticles.
Proteomics on isolated microparticles will be per-
formed on selected samples and analyzed. Lupus anti-
coagulants are phospholipid-dependent coagulation
inhibitors that are detected with a functional assay
based on a clotting test. Platelet reactivity can be
assessed with the platelet activation test (PACT), a
whole blood functional test of the total platelet re-
sponse capacity.
Arterial stiffness measured by pulse wave velocity
(PWV) is a predictor of cardiovascular events. The Arter-
iograph (TensioMed, Budapest, Hungar. EC Directive 93/
42/EEC, ISO 13485:2003, ISO 13485:2004) is an oscillo-
metric arterial stiffness measurement, which will be per-
formed directly before the CCT in the UMC Utrecht.
Outcome
The primary outcome is the presence of relevant CAD
that will be defined as one or more of the following on
CT: a CACS ≥100 AU or luminal stenosis ≥ 50%. All mea-
surements will be discussed with participants individually
under supervision of a vascular specialist. For manage-
ment of cardiovascular risk factors, the current guideline
on European Guidelines on cardiovascular disease preven-
tion will be used [80]. All patients with relevant CAD are
discussed with a cardiologist. Management and treatment
decisions are left to the discretion of the cardiologist. As a
general rule, participants with a CACS of 100-400 AU
without obstructive CAD will receive lifestyle advice and
may be recommended to initiate treatment with statins
[81, 82]. Participants with a CACS ≥ 400 AU or coronary
artery stenosis ≥ 50% will be offered a consultation with a
cardiologist to discuss management options. Other re-
levant cardiac findings will be discussed with the cardio-
logist. If incidental extra-cardiac findings, such as lung or
liver lesions, are considered to be of clinical importance,
recommendations of further testing, follow-up or referral
to another specialist will be made.
Sample size calculation
No prospective studies have performed CCT (including
both CACS and CCTA) in women with reproductive
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disorders as part of long-term cardiovascular follow up.
The estimation of the expected necessary sample size is
based on α = 0.05 and desired power = 0.90. In addition,
the background prevalence of coronary plaque (both
non-calcified and calcified) in asymptomatic, healthy fe-
males ≥ 45 years old based on the CCTA study by Kim
et al. (2013) is estimated 6.7% [83]. We presume a rela-
tive risk of around 2 for the development of CVD is
women with reproductive disorders [44]. This leads to
an (conservative) estimated prevalence of coronary ar-
tery disease (plaque) of 13.4% (95% CI 10.0 - 17.6) and a
minimal sample size of at least 261 CCT’s in both the
HPD and the PCOS/POI group.
Based on these results and given the radiation-induced
health risks, initial inclusion will be confined to women
who are 45-55 years old and we will perform an interim
analysis after 300 CCT’s (100 in patients with HPD, 100
in patients with PCOS and 100 in patients with POI). If
the prevalence of plaque as seen on CCTA is ≥ 10%,
which is the lower bound of the 95% CI in our estimated
prevalence of coronary artery disease, we expect to find
significant differences compared to controls. In that
case, we will perform the remaining 300 CCT’s (200 in
patients with HPD and 100 in patients with PCOS/POI),
leading to a total of 300 CCT’s in patients with HPD
and 300 CCT’s in patients with PCOS/POI. The age
range (40-45 years and/or ≥ 55 years) and group com-
position for later inclusion may be adapted based on the
findings of the interim analysis. If the prevalence of
plaque as seen on CCT is ≤ 10%, we do not expect to
find any significant differences compared to controls and
therefore we will withdraw the remaining CCTA’s and
focus on CACS only.
Statistical analysis
Data analysis will be performed using SPSS. A probabil-
ity (p) less than 0.05 will be considered significant. The
characteristics of participants will be described using
means +/− standard deviations for continuous variables
using a two tailed independent t-test for comparison be-
tween groups (e.g. plaque burden). Categorical variables
will be expressed as numbers (percentages) or medians
(with inter quartile ranges) and compared with a chi-
square test (e.g. CACS percentiles). Identical tests will
be performed for circulating biomarkers. If several vari-
ables are identified to be statistically associated with car-
diovascular risk factors, multiple linear regression or
multiple logistic regression will be performed to identify
the most important associations, appropriate to the end-
point chosen.
Ethical considerations
This study has been approved by the Medical Research
Ethics Committee of the University Medical Center
Utrecht (MEC number 15-508). This trial is registered in
the Dutch Trial Register, NTR 5531, http://www.trialre-
gister.nl/trialreg/admin/rctview.asp?TC=5531, date of
registration: October 21st, 2015.
Discussion
In this multicenter, prospective, cross-sectional study in
patients with a reproductive disorder (PCOS, POI or
HPD) we aim to assess CVD by CCT imaging (both
CACS and CCTA) and CSC. Given the increased risk on
CVD later in life, we believe the low radiation exposure
is justified. Moreover, a substudy of the association of
cell-based biomarkers and CCT will be performed.
The results of this study will provide insights in the
added value CT imaging in the detection of cardiovascu-
lar disease. Ultimately, these insights can lead to im-
proved cardiovascular prediction models in these
women and may provide an opportunity for adjusted
preventive strategies.
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